Castle Biosciences reported Q4 2025 revenue of 87010000 with core revenue driver test report volume up 42% year-over-year. The quarter produced an operating loss of 3827000 and a net loss of 2332000, while non-dermatologic test revenue increased to 38400000.

Castle Biosciences delivered a strong third quarter in 2025, achieving $83 million in revenue and a total test report volume of 26,841. The company saw significant growth in its core dermatologic and gastrointestinal testing franchises, with DecisionDx-Melanoma and TissueCypher each surpassing 10,000 test reports. This strong performance led to an increase in the full-year 2025 revenue guidance.

Castle Biosciences delivered a strong second quarter in 2025, achieving $86 million in revenue. The company saw solid year-over-year test volume growth in its core revenue drivers, DecisionDx-Melanoma and TissueCypher, which exceeded expectations. This performance led to an upward revision of the full-year 2025 revenue guidance.

Castle Biosciences reported a strong start to 2025 with significant increases in revenue and test report volume in the first quarter, driven by core revenue drivers like DecisionDx-Melanoma and DecisionDx-SCC. The company also raised its full-year 2025 revenue guidance.

Castle Biosciences delivered an outstanding fourth quarter, achieving 31% revenue growth and a significant increase in net income compared to the same period in 2023. The company also reported a substantial increase in total test reports delivered, particularly in TissueCypher Barrett's Esophagus tests.

Castle Biosciences reported strong Q3 2024 results, with a 39% increase in revenue compared to Q3 2023, reaching $85.8 million. The company also saw a 41% increase in total test reports delivered. As a result of this strong performance, Castle Biosciences raised its full-year 2024 revenue guidance to $320-330 million.

Castle Biosciences reported a strong second quarter with a 74% increase in revenue compared to the same period last year. The company also raised its full-year revenue guidance to $275-300 million.

Castle Biosciences reported a strong start to 2024 with a 74% increase in revenue compared to Q1 2023, reaching $73 million. The company also raised its full-year 2024 revenue guidance to $255-265 million, reflecting confidence in the business.

Castle Biosciences reported a strong fourth quarter and full-year 2023, with a 72% increase in Q4 revenue compared to the same period in 2022. The company delivered 20,284 total test reports in Q4, a 60% increase year-over-year. Full-year 2023 revenue reached $219.8 million, a 60% increase compared to 2022.

Castle Biosciences reported strong Q3 2023 results, with a 66% increase in revenue compared to Q3 2022, reaching $61.5 million. The company also saw a 52% increase in total test reports delivered. Due to consistent performance, Castle Biosciences raised its full year 2023 revenue guidance to at least $200 million.

Castle Biosciences reported strong Q2 2023 results, with a 44% increase in revenue to $50.1 million and a 52% increase in total test reports delivered. The company raised its full-year 2023 revenue guidance to at least $180 million.

Castle Biosciences reported a strong start to 2023 with a 57% increase in revenue compared to Q1 2022, driven by significant test report volume growth. The company reaffirmed its full-year 2023 revenue guidance of $170-180 million.

Castle Biosciences reported strong fourth-quarter results with a 53% increase in revenue to $38.3 million and a 53% increase in total test reports delivered. The company anticipates generating between $170-180 million in total revenue in 2023.

Castle Biosciences announced strong Q3 2022 results, with revenue growing by 58% compared to Q3 2021, reaching $37.0 million. The company delivered 12,114 total test reports, a 57% increase over the same period last year. They are increasing 2022 revenue guidance to $132-137 million.

Castle Biosciences reported a 53% increase in revenue compared to Q2 2021, reaching $34.8 million. The company delivered 11,034 total test reports, a 57% increase over the same period last year. They are raising 2022 revenue guidance to $130-135 million.

Castle Biosciences reported an 18% increase in revenue compared to Q1 2021, driven by a 68% increase in total test reports delivered. The company is focused on its dermatology business, pipeline initiatives, and strategic opportunities.

Castle Biosciences reported a 45% increase in revenue for Q4 2021 compared to the same period in 2020, with significant growth in total gene expression profile test reports delivered. The company's full-year revenue increased by 50% compared to 2020. They also successfully completed two acquisitions.

Castle Biosciences announced strong Q3 2021 results, with a 54% increase in revenue compared to the same period in 2020, reaching $23.5 million. The company also reported a total gene expression profile test reports delivered of 7,727. They are on track to achieve 2021 total revenue guidance of $89-93 million.

Castle Biosciences reported strong Q2 2021 results with a 79% increase in revenue compared to Q2 2020. The company also saw a 70% increase in DecisionDx-Melanoma test reports and raised its 2021 revenue guidance to $89-93 million.

Castle Biosciences announced strong Q1 2021 results with a 31% revenue increase compared to Q1 2020. The company is making progress on growth initiatives, including the acquisition of Myriad's myPath Melanoma laboratory and the development of a new test for systemic therapy response in patients with psoriasis and atopic dermatitis. They are providing 2021 revenue guidance of $80-83 million.

Castle Biosciences reported Q4 2020 revenues of $17.3 million, a slight decrease from $17.6 million in Q4 2019. The company delivered 5,157 total gene expression profile test reports, compared to 4,914 in the same period in 2019. Gross margin remained strong at 85%.

Castle Biosciences announced its Q3 2020 financial results, with revenues reaching $15.2 million, a 3% increase compared to Q3 2019. The company also saw a return to year-over-year growth in DecisionDx-Melanoma report volume and launched two new tests: DecisionDx-SCC and DecisionDx DiffDx-Melanoma.

Castle Biosciences reported Q2 2020 revenues of $12.7 million, an 18% increase compared to Q2 2019. The company delivered 3,008 DecisionDx-Melanoma test reports, a 19% decrease year-over-year, and maintained a strong gross margin of 83%. Operating cash flow was positive at $13.5 million.

Castle Biosciences reported a strong first quarter with a 100% increase in revenue to $17.4 million compared to Q1 2019. The company delivered 4,574 DecisionDx-Melanoma test reports, a 42% increase year-over-year. However, due to the COVID-19 pandemic, the company has suspended its 2020 revenue guidance.

Castle Biosciences reported strong Q4 2019 results with revenue of $17.6 million, a significant increase compared to Q4 2018. The company also saw growth in DecisionDx-Melanoma and DecisionDx-UM test reports delivered.